28-Aug-2026
These ten healthcare stocks posted the biggest gains over the past month
Seeking Alpha News (Fri, 28-Aug 7:54 AM ET)
Xencor Reports Second Quarter 2026 Financial Results
Business Wire (Wed, 5-Aug 4:01 PM ET)
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris U.S. Royalty Matter
Business Wire (Wed, 29-Jul 4:01 PM ET)
Market Chameleon (Mon, 20-Jul 7:06 AM ET)
Business Wire (Fri, 17-Jul 9:11 AM ET)
PRNewswire (Mon, 6-Jul 11:20 AM ET)
XmAb942 and XmAb412 Set New Benchmarks in Autoimmune Disease Therapy, Xencor Reports at DDW
Market Chameleon (Mon, 4-May 5:23 AM ET)
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
Xencor trades on the NASDAQ stock market under the symbol XNCR.
As of August 28, 2026, XNCR stock price declined to $26.06 with 1,977,173 million shares trading.
XNCR has a beta of 0.02, meaning it tends to be less sensitive to market movements. XNCR has a correlation of 0.00 to the broad based SPY ETF.
XNCR has a market cap of $1.94 billion. This is considered a Small Cap stock.
Last quarter Xencor reported $51 million in Revenue and -$.29 earnings per share. This beat revenue expectation by $34 million and exceeded earnings estimates by $.54.
In the last 3 years, XNCR traded as high as $30.61 and as low as $6.92.
The top ETF exchange traded funds that XNCR belongs to (by Net Assets): IJR, XBI, IWM, VTI, SPSM.
XNCR has outperformed the market in the last year with a price return of +223.7% while the SPY ETF gained +19.7%. XNCR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +117.7% and +11.7%, respectively, while the SPY returned +2.2% and -0.9%, respectively.
XNCR support price is $27.65 and resistance is $30.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XNCR shares will trade within this expected range on the day.
